デフォルト表紙
市場調査レポート
商品コード
1763911

治療薬モニタリング市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、技術別、地域別セグメント、競合、2020年~2030年

Therapeutic Drug Monitoring Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Technology, By Region and Competition, 2020-2030F


出版日
ページ情報
英文 185 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

治療薬モニタリング市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、技術別、地域別セグメント、競合、2020年~2030年
出版日: 2025年06月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

治療薬モニタリングの世界市場は、2024年に15億米ドルと評価され、2030年には18億2,000万米ドルに達し、CAGR 3.47%で拡大すると予測されています。

治療薬モニタリング(TDM)はプレシジョン・メディシンの重要な要素であり、臨床医が血流中の薬物濃度を測定し、最適な安全性と有効性を得るために治療を調整することを可能にします。TDMは、治療域が狭い薬剤や個人によって代謝が異なる薬剤にとって特に重要です。てんかん、がん、心血管疾患、自己免疫疾患などの慢性疾患の増加により、日常的な薬物モニタリングの必要性が顕著になってきています。特に免疫抑制剤、抗生物質、抗てんかん薬などの長期治療を受けている患者は、副作用を回避しながら治療効果を維持するために、頻繁なモニタリングを必要としています。このような需要があるにもかかわらず、市場には、機器の高コスト、専門知識の必要性、資源の制約や認知度の低さによる新興国市場での採用の制限といったハードルが存在します。

市場概要
予測期間 2026-2030
市場規模:2024年 15億米ドル
市場規模:2030年 18億2,000万米ドル
CAGR:2025年~2030年 3.47%
急成長セグメント 抗てんかん薬
最大市場 北米

市場促進要因

ヘルスケア産業の成長

主な市場課題

検査とインフラの高コスト

主な市場動向

個別化医療に対する需要の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の治療薬モニタリング市場に与える影響

第5章 世界の治療薬モニタリング市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別(抗てんかん薬、抗生物質、免疫抑制薬、抗不整脈薬、気管支拡張薬、向精神薬、その他)
    • 技術別(免疫測定法、化学発光免疫測定法、比色免疫測定法、蛍光免疫測定法、放射免疫測定法、その他)
    • 地域別
    • 企業別(2024)
  • 市場マップ

第6章 北米の治療薬モニタリング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の治療薬モニタリング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の治療薬モニタリング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の治療薬モニタリング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの治療薬モニタリング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 混乱:紛争、パンデミック、貿易障壁

第14章 世界の治療薬モニタリング市場:SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • Roche AG
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • bioMerieux, Inc.
  • Alere, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 5028

The Global Therapeutic Drug Monitoring Market was valued at USD 1.50 Billion in 2024 and is projected to reach USD 1.82 Billion by 2030, expanding at a CAGR of 3.47%. Therapeutic Drug Monitoring (TDM) is a critical component of precision medicine, enabling clinicians to measure drug levels in the bloodstream to tailor treatment for optimal safety and efficacy. TDM is particularly important for medications with narrow therapeutic windows or variable metabolism across individuals. With rising incidences of chronic conditions such as epilepsy, cancer, and cardiovascular and autoimmune diseases, the need for routine drug monitoring is becoming more pronounced. Patients undergoing long-term treatments-especially with immunosuppressants, antibiotics, or antiepileptic drugs-require frequent monitoring to maintain therapeutic effectiveness while avoiding adverse effects. Despite this demand, the market encounters hurdles, such as the high cost of equipment, the need for technical expertise, and limited adoption in developing regions due to resource constraints and low awareness.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.50 Billion
Market Size 2030USD 1.82 Billion
CAGR 2025-20303.47%
Fastest Growing SegmentAntiepileptic Drug
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare sector, with annual revenues exceeding USD 4 trillion, is a key catalyst for the therapeutic drug monitoring market. Pharmaceuticals and biotechnology contribute nearly USD 850 billion, while medical technology and diagnostics generate over USD 400 billion. As healthcare systems worldwide evolve toward precision-driven, patient-centric models, TDM is gaining importance for its ability to optimize treatment efficacy and minimize adverse drug reactions. Growing emphasis on individualized therapy and safe medication practices positions TDM as an integral part of modern clinical care protocols.

Key Market Challenges

High Cost of Testing and Infrastructure

The substantial cost associated with implementing and maintaining TDM capabilities represents a significant challenge for broader adoption. Establishing a dedicated TDM facility necessitates advanced instruments such as liquid chromatography-mass spectrometry (LC-MS), immunoassay analyzers, and robust data management systems. These high capital investments are coupled with recurring expenses related to maintenance, quality control, and skilled labor. Additionally, compliance with stringent regulatory and quality standards further escalates the cost of infrastructure. These barriers are particularly restrictive for smaller healthcare facilities and institutions in developing economies.

Key Market Trends

Rising Demand for Personalized Medicine

A major trend shaping the TDM market is the increasing adoption of personalized medicine, valued globally at approximately USD 512 billion in 2022. Personalized medicine aims to deliver treatments tailored to an individual's genetic profile, lifestyle, and physiological response. In this context, TDM serves as a vital enabler by allowing healthcare professionals to monitor drug concentrations in real-time, ensuring therapeutic levels are achieved without toxicity. This is especially crucial for drugs with narrow therapeutic indices. The convergence of TDM with pharmacogenomics and precision diagnostics is reinforcing its role in developing more accurate, patient-specific treatment regimens, ultimately enhancing clinical outcomes.

Key Market Players

  • Roche AG
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • bioMerieux, Inc.
  • Alere, Inc.

Report Scope

In this report, the Global Therapeutic Drug Monitoring Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic Drug Monitoring Market, By Drug Class:

  • Antiepileptic Drug
  • Antibiotic Drug
  • Immunosuppressant Drug
  • Antiarrhythmic Drug
  • Bronchodilator Drug
  • Psychoactive Drug
  • Others

Therapeutic Drug Monitoring Market, By Technology:

  • Immunoassay
  • Chemiluminescence Immunoassay
  • Colorimetric Immunoassay
  • Fluorescence Immunoassay
  • Radioimmunoassay
  • Others

Therapeutic Drug Monitoring Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Drug Monitoring Market.

Available Customizations

Global Therapeutic Drug Monitoring Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Therapeutic Drug Monitoring Market

5. Global Therapeutic Drug Monitoring Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Antiepileptic Drug, Antibiotic Drug, Immunosuppressant Drug, Antiarrhythmic Drug, Bronchodilator Drug, Psychoactive Drug, Others)
    • 5.2.2. By Technology (Immunoassay, Chemiluminescence Immunoassay, Colorimetric Immunoassay, Fluorescence Immunoassay, Radioimmunoassay, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Therapeutic Drug Monitoring Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Therapeutic Drug Monitoring Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Technology
    • 6.3.2. Mexico Therapeutic Drug Monitoring Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Technology
    • 6.3.3. Canada Therapeutic Drug Monitoring Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Technology

7. Europe Therapeutic Drug Monitoring Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Therapeutic Drug Monitoring Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Technology
    • 7.3.2. Germany Therapeutic Drug Monitoring Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Therapeutic Drug Monitoring Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Therapeutic Drug Monitoring Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Therapeutic Drug Monitoring Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Technology

8. Asia Pacific Therapeutic Drug Monitoring Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Therapeutic Drug Monitoring Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Therapeutic Drug Monitoring Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Technology
    • 8.3.3. South Korea Therapeutic Drug Monitoring Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Technology
    • 8.3.4. Japan Therapeutic Drug Monitoring Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Therapeutic Drug Monitoring Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Technology

9. South America Therapeutic Drug Monitoring Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutic Drug Monitoring Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Therapeutic Drug Monitoring Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Therapeutic Drug Monitoring Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Therapeutic Drug Monitoring Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutic Drug Monitoring Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Therapeutic Drug Monitoring Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Therapeutic Drug Monitoring Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Therapeutic Drug Monitoring Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Roche AG
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Siemens Healthcare GmbH
  • 16.3. Thermo Fisher Scientific, Inc.
  • 16.4. Bio-Rad Laboratories, Inc.
  • 16.5. Beckman Coulter, Inc.
  • 16.6. Abbott Laboratories, Inc.
  • 16.7. Agilent Technologies, Inc.
  • 16.8. bioMerieux, Inc.
  • 16.9. Alere, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer